# Diabetes Research Hub — Monitor Report
**Run date:** 2026-06-12 (automated review run)
**Previous monitor report:** 2026-06-11
**Comparison window:** snapshots 2026-06-11 → 2026-06-12

---

## File System Status

The hub is healthy and current. Today's pipeline outputs all wrote cleanly:

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-06-12 07:04 | Fresh |
| clinical_trials_summary.md | 2026-06-12 07:04 | Fresh |
| pubmed_recent_latest.json | 2026-06-12 07:05 | Fresh |
| pubmed_recent_summary.md | 2026-06-12 07:05 | Fresh |
| hub_monitor_report.md | 2026-06-12 07:05 | Fresh |
| literature_gap_report.md | 2026-06-11 08:08 | 1 day old — OK |
| literature_gap_data.json | 2026-04-20 15:35 | **Stale (53 days)** |

hub_monitor.py tracked 920 files: 4 new, 29 modified, 0 removed. The dashboards and evidence/citation JSONs last refreshed 2026-06-11 (the daily `iterate` run). Note: `literature_gap_data.json` (the raw gap matrix) has not been regenerated since April 20 — the gap **report** is re-derived daily but the underlying PubMed co-publication matrix is nearly two months old. The monitor flagged 705 result files older than 14 days, which is expected for the dated snapshot archive.

---

## Clinical Trial Changes

Snapshot diff (06-11 → 06-12): **1 new trial, 1 removed, 0 status changes, 0 new results posted.** Quiet day.

- **New:** NCT07642518 — Transcutaneous Auricular Vagus Nerve Stimulation in Type 2 Diabetes (Nanjing Drum Tower Hospital; NOT_YET_RECRUITING; NA phase). Minor.
- **Removed/dropped from query:** NCT06184568 — IBI362 vs Semaglutide in Chinese adults (Innovent Biologics; Phase 3, ACTIVE_NOT_RECRUITING). Dropped out of the search result set rather than terminated; worth a one-off confirmation it wasn't withdrawn.

Totals are stable: **807 unique trials**, 264 RECRUITING, 124 Phase 3, 46 of those Phase 3 + RECRUITING.

**Key Phase 3 trials to keep watching (key sponsors, currently RECRUITING):**

- **VX-880 / zimislecel (Vertex)** — NCT06832410 and NCT04786262, both Phase 3 RECRUITING. The stem-cell islet program remains the highest-impact T1D-cure asset in the tracker. No results posted yet.
- **Baricitinib (Eli Lilly)** — NCT07222332 (preserve beta-cell function) and NCT07222137 (delay Stage 3 T1D), both Phase 3 RECRUITING. Repurposed JAK inhibitor in T1D — directly relevant to our Drug Repurposing and T1D Immunotherapy domains.
- **Insulin icodec (Novo Nordisk)** — NCT07076199, Phase 3 RECRUITING (weekly insulin).
- **CagriSema (Novo Nordisk)** — NCT07564414, Phase 3 RECRUITING (dose-ranging).

**Recently posted results worth a look** (already in the corpus, posted within ~2 weeks):

- NCT04965935 — SGLT2 inhibitors (Phase 3), results posted 2026-06-08.
- NCT05813912 — Insulin icodec weekly (Novo, Phase 3), results posted 2026-06-03.
- NCT05925920 — ENT-03 (subcutaneous), Phase 1, results posted 2026-06-01.

---

## PubMed Highlights

Latest pull: **165 unique papers** across 16 alert domains, 30-day lookback. Day-over-day: **39 new papers, 37 dropped.**

**Cross-domain papers (highest priority — 13 total; the most notable new/recent ones):**

- **[42277427]** Lentiviral GLP-1 gene therapy elicits stage-dependent β-cell regeneration in diabetic models — *T2D GLP-1 New × Gene Therapy* (2026-Jun-12). New today; sits squarely at a Tier 1 intersection.
- **[42269843]** Targeting shared immune pathways in MS and type 1 diabetes — *T1D Immunotherapy × teplizumab* (2026-Jun-10).
- **[42276507]** Integrating oxidative-stress profiling with retinal imaging for precision management — *Biomarker × Complications* (2026-Jun-11).
- **[42268809]** Microbiome-informed strategies for predicting pregnancy complications — *Biomarker × Microbiome* (2026-Jun-10).
- **[42259339]** Orforglipron compared with dapagliflozin in adults with T2D — *orforglipron × dapagliflozin* (2026-Jun-08); head-to-head oral GLP-1 vs SGLT2.
- **[42264536]** Retatrutide triple-agonist review — *T2D GLP-1 New × retatrutide* (2026-Jun-09); aligns with the ADA Scientific Sessions readout below.

**Key-therapy tracker:** all 8 tracked therapies (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin) have fresh hits. Teplizumab is the most active (4 distinct recent papers, including a CGM-based early-response assessment). No anomalous spikes or silences across domains.

---

## Gap Analysis Summary

Top under-researched intersections (gap score, joint pubs — all BRONZE / single-source, per Doctrine):

1. **Beta Cell Regen × Health Equity** — 100.0 (0 joint pubs)
2. **Insulin Resistance × Islet Transplant** — 100.0 (1)
3. **Islet Transplant × Drug Repurposing** — 100.0 (0)
4. **Islet Transplant × Health Equity** — 100.0 (0)
5. **Gene Therapy × LADA** — 100.0 (0)

**Tier 1 alignment:** Item #3 (Islet Transplant × Drug Repurposing) maps directly onto Doctrine Tier 1 area #4 (Drug Repurposing Computational Screening) and the existing islet-repurposing work in the hub. Items #1 and #4 touch Tier 1 #6 (Epidemiological / Health Equity). These remain the strongest candidates for a defensible computational contribution. Today's new gene-therapy/GLP-1 β-cell regeneration paper [42277427] is also adjacent to the Gene Therapy gaps.

Caveat unchanged: gap scores are relative co-publication measures, not absolute need, and the source matrix is from April 20 (see staleness flag).

---

## Breaking News (web check, last ~7 days)

- **ADA 85th Scientific Sessions, New Orleans, June 5–8, 2026** drove the cycle. Headline: **retatrutide (Eli Lilly) first Phase 3 T2D + obesity results announced June 6** — positive weight, A1C, and secondary outcomes (OSA, knee OA pain) for the GIP/GLP-1/glucagon triple agonist. This corroborates tracker trials NCT06297603 / NCT05929079 / NCT06260722 (all Phase 3, ACTIVE_NOT_RECRUITING) and the new PubMed review [42264536].
- **Survodutide (Boehringer, SYNCHRONIZE-1)** — Phase 3 obesity data, up to 16.6% weight loss at 76 weeks, presented at the same meeting.
- No *new* FDA diabetes actions in the last 7 days. For context, orforglipron was approved Apr 1, 2026 and Tzield/teplizumab's pediatric sNDA Apr 22 — both already captured and outside the 7-day window.

Evidence note (Doctrine): the news events above are GOLD-level for the fact of the regulatory action / pre-specified Phase 3 readout at a major congress; any mechanistic or comparative claims drawn from the PubMed papers remain at the evidence level of the individual paper and are not yet independently corroborated in this hub.

---

## Recommended Actions

1. **Refresh the gap matrix.** `literature_gap_data.json` is 53 days old while everything else is current. Run: `python project1_literature_gap_analysis.py` so the gap report is derived from fresh co-publication counts.
2. **Confirm NCT06184568 status.** The Innovent IBI362-vs-semaglutide Phase 3 dropped out of today's query set — verify it was a query artifact, not a withdrawal/termination, before assuming it's gone.
3. **Review cross-domain paper [42277427]** (lentiviral GLP-1 gene therapy → β-cell regeneration) — relevant to Gene Therapy and T2D GLP-1 domains, and adjacent to the Gene Therapy × LADA gap. Consider adding to the paper library / evidence network.
4. **Add Phase 3 watch entries to clinical_trials_summary.md.** The "Notable Trials to Watch" table is still empty. Seed it with the Vertex VX-880 pair and the two Lilly baricitinib T1D trials — the highest-signal recruiting Phase 3 assets in the tracker.
5. **Log the retatrutide ADA readout** against the existing retatrutide Phase 3 NCTs in the tracker (combination/timeline intelligence — Tier 1 area #3).
6. No action needed on trial-volume monitoring; the day was quiet (net 0 trials, 0 status changes).

---
*Generated by the Diabetes Research Hub automated monitor — review run, no source files modified.*
